Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 5.5%

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) traded up 5.5% on Friday . The company traded as high as $13.50 and last traded at $13.30. 12,811 shares were traded during trading, a decline of 84% from the average session volume of 78,800 shares. The stock had previously closed at $12.61.

Gyre Therapeutics Trading Up 1.1 %

The company has a 50-day moving average price of $12.22 and a two-hundred day moving average price of $16.05.

Gyre Therapeutics (NASDAQ:GYRE) last posted its earnings results on Thursday, May 9th. The company reported $0.04 earnings per share for the quarter. The firm had revenue of $27.17 million for the quarter. On average, sell-side analysts predict that Gyre Therapeutics, Inc. will post -0.45 EPS for the current year.

Insider Activity at Gyre Therapeutics

In other Gyre Therapeutics news, Director Nassim Usman sold 20,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $14.13, for a total value of $282,600.00. Following the transaction, the director now directly owns 1,636 shares in the company, valued at approximately $23,116.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.92% of the stock is owned by corporate insiders.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.